Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases


Abstract:

Pioglitazone (PGZ)is a peroxisome proliferator-activated receptor agonist. Its role in the inflammatory response modulation paves the way for additional therapeutic applications. The purpose of this study was to develop a pioglitazone nanoemulsion (PGZ-NE)in order to investigate its anti-inflammatory efficacy on the skin. To that end, an NE vehicle developed for skin delivery was optimized and characterized. The resulting PGZ-NE showed good anti-inflammatory efficacy by decreasing the expression of inflammatory cytokines IL-6, IL-1β and TNF-α. The properties of the developed nanocarrier allowed achievement of a high permeation flux of PGZ through the skin as well as a high retained amount in the skin, likely due to the depot effect of ingredients, which assured a prolonged local action, with good skin tolerability among participating individuals. Consequently, these results suggest that PGZ-NE may be used as an alternative treatment for inflammatory skin diseases such as rosacea, atopic dermatitis or psoriasis.

Año de publicación:

2019

Keywords:

  • NANOEMULSIÓN
  • Pioglitazone
  • anti-inflammatory activity
  • Skin disorders
  • cytokines

Fuente:

scopusscopus

Tipo de documento:

Article

Estado:

Acceso restringido

Áreas de conocimiento:

  • Farmacología
  • Descubrimiento de fármacos
  • Biomedicina

Áreas temáticas de Dewey:

  • Farmacología y terapéutica
Procesado con IAProcesado con IA

Objetivos de Desarrollo Sostenible:

  • ODS 3: Salud y bienestar
  • ODS 10: Reducción de las desigualdades
  • ODS 9: Industria, innovación e infraestructura
Procesado con IAProcesado con IA